The danger of the SNAP back; biopharma-academic collabs; genetic counselors wanted; and much more

April 2, 2023 Check out STAT+

Sponsored By

By Torie Bosch Editor, First Opinion

This week on First Opinion: how the end of expanded SNAP benefits will quite literally hurt millions of children; the dire need for more genetic counselors in an age of at-home DNA testing; how to make biopharma-academic collaborations fruitful; and more. You can read all of the week's essays here. Have a potential piece for First Opinion? Send it to first.opinion@statnews.com.

Allison Dinner/AP Rolling back SNAP benefits puts millions of children at risk of hunger and long-term health consequences Even pre-pandemic, SNAP benefits were insufficient to afford a healthy diet. Now, with inflation, the situation will be even worse. By Megan Sandel and Charlotte Bruce Biden's budget boosts funds for future pandemics, but cuts them for current ones Under the proposed Biden budget, U.S. funding for global tuberculosis, malaria, and HIV/AIDS all get scaled back. By Colin Puzo Smith Why the rise of DNA testing is creating challenges — and an opportunity People who seek elective genetic testing may find it difficult to understand the results on their own. Genetic counselors can help. By Noura Abul-Husn Adobe STAT+ | 3 keys to successful biopharma-academia drug development collaborations Many sponsored research collaborations that hope to tap into academia fail. But there are ways to make them work. By Dave Greenwald To deal with the next pandemic, the FDA needs an Office of Preparedness and Response It would be naive to think that the FDA could respond to an H5N1 flu epidemic as quickly as it did Covid in 2020. By Robert Kadlec and Enlli Lewis STAT+ | Strengthen science by funding living evidence synthesis The living evidence model can provide immense value to countless fields, but is yet to be widely implemented beyond health care. By Jordan Dworkin and Julian Elliott

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying First Opinion? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser